AVI-6002: Phase I data

Additional data from 5 healthy volunteers in the sixth dose cohort of a double-blind, placebo-controlled Phase I trial showed that single doses of 9 mg/kg IV AVI-6002 led to no safety concerns or treatment-related changes in kidney function. In all 30 subjects, the most common adverse events were headache, nausea and sinus congestion. Moderate uveitis was observed in 1 subject. Data were presented at the European Congress of Clinical Microbiology and Infectious Diseases in London. Last November, AVI reported data from 25 healthy volunteers in the first 5 cohorts of the trial showing no safety concerns for single ascending-doses of 0.01, 0.1, 1, 3 or 6 mg/kg AVI-6002 (see BioCentury, Nov. 7, 2011). ...